Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines.
- Author:
Sang Young RYU
1
;
Kidong KIM
;
Woo Sik LEE
;
Hee Chung KWON
;
Kee Ho LEE
;
Chang Min KIM
;
Soon Beom KANG
Author Information
- Publication Type:Original Article ; Clinical Trial
- Keywords: p53; Adenoviruses; Gene therapy; Cisplatin
- MeSH: Adenoviridae; Adenoviruses, Human; Blotting, Western; Cell Count; Cell Line; Cisplatin; DNA; Genes, p53; Genetic Therapy; Lifting; Ovarian Neoplasms; Ploidies; Proteins
- From:Journal of Gynecologic Oncology 2009;20(1):48-54
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: This study was to investigate the synergistic growth inhibitory effect by combination of adenovirus mediated p53 gene transfer and cisplatin in ovarian cancer cell lines with different p53 gene mutation patterns. METHODS: Three ovarian cancer cell lines, p53 deleted SKOV3, p53 mutated OVCAR-3, and PA-1 with wild-type p53 were transduced with human adenovirus vectors carrying p53 gene (Ad-p53) and treated with a sublethal concentration of cisplatin before and after Ad-p53. The cell number was counted daily for 5 days after Ad-p53 transduction. Western blotting was used to identify p53 and p21 protein expressions, and flow cytometric analysis was performed to investigate any change of DNA ploidy after Ad-p53 transfer. RESULTS: Ad-p53 transduced cells successfully expressed p53 and p21 proteins after 48 hours of Ad-p53 transduction. Synergistic growth inhibition by combination of Ad-p53 and cisplatin was detected only in SKOV3 and OVCAR-3 cells, but not in PA-1 cells. In p53 deleted SKOV3 cells, cisplatin treatment after Ad-p53 showed higher growth inhibition than the treatment before Ad-p53 transduction, and reverse relationship was observed in p53 mutated OVCAR-3 cells. In SKOV3 cells, the fraction of cells at G2/M phase increased after cisplatin treatment, however, it decreased dramatically with Ad-p53 transduction. CONCLUSION: The synergistic growth inhibition by combination of Ad-p53 and cisplatin may depend on the p53 status and the temporal sequence of cisplatin treatment, suggesting judicious selective application of this strategy in clinical trials.
